
    
      Two groups of patients with multiple myeloma were initially studied: bortezomib-naïve and
      bortezomib-treated. Following Amendment 2, only bortezomib-naïve patients were enrolled.
      Study results were reported in 2 parts, depending on whether a patient received prior
      bortezomib.
    
  